Regorafenib eye drops were developed for treating
age-related macular degeneration. This study aimed to investigate the effects of this multi-
kinase inhibitor on intraocular pressure (IOP),
bleb formation, and conjunctival changes in a canine
filtration surgery model.
Glaucoma filtration surgery models were created in 24 eyes of 24 beagles. In experiment 1 (Ex 1),
regorafenib eye drops (
regorafenib group: n = 6) or a vehicle (control group, n = 6) were instilled twice daily for 4 weeks postoperatively. In experiment 2 (Ex 2),
regorafenib eye drops were instilled as in Ex 1 (
regorafenib group: n = 6) for 12 weeks while conventional intraoperative
mitomycin-C (MMC) was utilized (MMC group: n = 6), In Ex 1, only the
regorafenib group showed significant IOP reduction with a significantly higher
bleb score. Subconjunctival area,
collagen density, vessels, and cells showing proliferation and differentiation were lower in subconjunctival tissue in the
regorafenib group. In Ex 2, no significant difference was found in IOP reduction and
bleb formation between the
regorafenib and MMC groups;
bleb walls were significantly thicker and
collagen density and vessels were higher in the
regorafenib group; and no differences were observed in the above-mentioned cells. Thus,
regorafenib might be a better alternative to MMC for creating thicker and less ischemic
blebs in
glaucoma filtration surgery.